Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27570819 | 0.98 | PKM (0.71) | PKMEPHX1F2RDRD2DRD3 | |
| SCHEMBL20556166 | 0.82 | PKM (0.49) | PKMEPHX1CHRM2CHRM1CHRM3 | |
| SCHEMBL20556075 | 0.78 | PKM (0.46) | PKMEPHX1CHRM2CHRM1CHRM3 | |
| SCHEMBL27589350 | 0.78 | NPC1 (0.50) | PKMEPHX1 | |
| SCHEMBL4802576 | 0.76 | LMNA (0.49) | PKMFASNPOLB | |
| SCHEMBL3426971 | 0.75 | PKM (0.43) | PKMEPHX1CHRM2CHRM1CHRM3 | |
| SCHEMBL1596519 | 0.75 | EPHX1 (0.59) | PKMEPHX1POLB | |
| SCHEMBL10071982 | 0.73 | KMT2A (0.65) | PKMDRD2CHRM2CHRM1CHRM3 | |
| SCHEMBL14543277 | 0.73 | PKM (0.46) | PKMPOLBCHEK1 | |
| SCHEMBL14337147 | 0.72 | NPY5R (0.69) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114379-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | NR2E3, DRD2, HCRTR1 | PKM 1864/4885EPHX1 2126/4885F2R 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.